We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Isis Asset Man | ISIS | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | - |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| Top Posts |
|---|
Posted at 21/3/2018 07:48 by mrs barry Robert Spencer @jihadwatchRS Look at the rave reviews for my forthcoming book The History of Jihad From Muhammad to ISIS - the first comprehensive history of jihad from Egypt and Syria and Persia to Spain and India and Jerusalem and NYC - and beyond. Preorder here: hxxps://www.amazon.c |
Posted at 30/9/2017 14:54 by yf23_1 Interesting, I still can't understand how ISIS are not getting blasted from the air since Palmyra area is open desert so it should be easy with them out in the open. I suggest the Russian airforce does not have the capability to select targets accurately. |
Posted at 30/9/2017 13:50 by dr pigs blood 30.09.2017 Author: Alexander OrlovIt Seems that ISIS has No Intention of Surrendering Deir ez-Zor |
Posted at 15/5/2017 15:00 by barrie o bumma ISIS units now dissolving into "moderate" rebels.ISIS COMMANDERS JOIN “MODERATE&rdqu The ISIS commander Mahmoud Al-Faraj was said to be one of the highest-ranking commanders in Al-Mayadin Zero Hedge - MAY 15, 2017 |
Posted at 04/3/2017 20:17 by mad dog1 INVESTIGATE THIS: MCCAIN’S TIES TO ISIShxxp://www.infowars. |
Posted at 01/3/2017 12:12 by barrie o bumma ISIS leader 'admits DEFEAT in Iraq and orders militants to flee or kill themselves in suicide attacks'Abu Bakr al-Baghdadi is said to have issued a statement called 'farewell speech' Terror mastermind reported to have told fighters to flee, hide of launch attacks Comes as Iraqi army units seized back the last major road out of western Mosul UK Defence Minister Michael Fallon said he expected to see ISIS expelled from Iraq's major towns by the end of 2017 By Julian Robinson for MailOnline PUBLISHED: 09:50, 1 March 2017 | UPDATED: 10:10, 1 March 2017 Read more: |
Posted at 05/2/2017 20:09 by mrs barry Turkish police foil ISIS strike on Izmir holiday resort as 400 suspects including Syrian in contact with people smuggling gangs are arrested in nationwide dawn raidsTurkish police have conducted a series of anti-terror raids across the country 60 suspected jihadis have been arrested in capital Ankara according to reports Many of those arrested in Turkey are believed to be so-called foreign fighters ISIS is suspected of carrying out several bombings and a gun attack in Turkey By Darren Boyle for MailOnline PUBLISHED: 10:34, 5 February 2017 | UPDATED: 16:07, 5 February 2017 Read more: |
Posted at 11/10/2016 11:15 by cobaltsky4 Turkey's Dangerous Moves in Iraqby Burak Bekdil October 11, 2016 at 4:00 am Turkey's primary concern is not to drive ISIS out of Mosul but to make it a "Sunni-controlled city" after ISIS has been pushed out. And this ambition jeopardizes the planned assault on ISIS. Turkey's pretext is that its troops are in Iraq to "fight ISIS." That does not convince anyone. In a span of five years Turkey has had serious political and military tensions with several countries in its vicinity: Israel, Syria, Russia, Jordan, Egypt, Cyprus and Greece. Most recently, Iraq has also joined the club of hostilities surrounding Turkey. Despite the Iraqi government's vehement requests that Turkey withdraw its troops in Iraq, Ankara shrugs it off and says it will maintain its military presence in the neighboring country for "Iraq's stability." What a nice neighborly gesture! Behind the Turkish indifference lies sectarian concerns and ambitions. On October 1, Turkey's parliament extended the mandate of Turkish troops deployed in Iraqi territory by one more year. The troops are stationed near Bashiqa in northern Iraq -- as unwanted guests. That sparked a row with Baghdad and may further complicate the cold sectarian war between the Sunnis in the region, supported by Turkey, Saudi Arabia and Qatar, and their Shiite enemies, supported by Iran and the Shiite-controlled government in Baghdad. |
Posted at 16/10/2013 21:11 by bones The milestones keep coming:Press Release Isis Earns $10 Million Milestone Payment from Biogen Idec for Advancement of ISIS-DMPK Rx to Treat Myotonic Dystrophy CARLSBAD, Calif., Oct. 16, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $10 million milestone payment from Biogen Idec related to the selection and advancement of ISIS-DMPKRx to treat myotonic dystrophy type I (DM1). (Logo: hxxp://photos.prnews "We are very pleased with the successes we are having in our alliance with Biogen Idec. The progress we have made is evidenced in our spinal muscular atrophy and myotonic dystrophy programs. In less than two years, we discovered and advanced ISIS-DMPKRx into development, and we plan to begin human clinical studies next year," said B. Lynne Parshall, chief operating officer at Isis. "This summer we and Biogen Idec built upon our successful relationship to create a broad strategic alliance that combines our antisense technology with Biogen Idec's knowledge of neurodegenerative diseases and global reach, with the goal of bringing new drugs to the market to treat patients with neurological disorders." DM1 is a rare genetic neuromuscular disease characterized by progressive muscle atrophy, weakness and disabling muscle spasms. DM1, the most common form of muscular dystrophy in adults, is estimated to affect approximately 150,000 patients in the United States, Europe and Japan. DM1 is caused by a genetic defect in the dystrophia myotonica-protein kinase (DMPK) gene in which a sequence of three nucleotides repeats extensively, creating an abnormally long toxic RNA, which accumulates in the cell and prevents the production of proteins needed for normal cellular function. The severity and age of onset of DM1 correlates with the number of triplet repeats, which increases from one generation to the next. There are no disease-modifying therapies for patients with DM1 and current treatments are intended to manage symptoms and minimize disability. ISIS-DMPKRx is designed to correct the underlying genetic defect that causes DM1. "Myotonic dystrophy represents an ideal opportunity for antisense as the disease-causing gene produces a toxic RNA that is not easily targeted with traditional therapeutic approaches," said C. Frank Bennett, Ph.D., senior vice president of research at Isis. "In our preclinical studies, we and our collaborators, Drs. Charles Thornton and Thurman Wheeler at the University of Rochester, have been able to target the toxic RNA with antisense, remove the toxic RNA and restore normal cell function. We look forward to working with Biogen Idec to move this program into human clinical trials." In June 2012, Isis entered into an alliance with Biogen Idec to discover and develop an antisense drug targeting DMPK for the treatment of DM1. Under the terms of the agreement, Isis received an upfront payment of $12 million and is eligible to receive up to $59 million in milestone payments associated with the clinical development of ISIS-DMPKRx, including this $10 million milestone payment. Biogen Idec has the option to license ISIS-DMPKRx from Isis up through completion of the Phase 2 study. Isis could receive up to another $200 million in a license fee and regulatory milestone payments plus double-digit royalties on sales of ISIS-DMPKRx. Isis is responsible for global development of ISIS-DMPKRx through completion of Phase 2 clinical studies, with Biogen Idec providing advice on the clinical study design and regulatory strategy. If Biogen Idec exercises its option, it will assume global development, regulatory and commercialization responsibilities. ABOUT ISIS PHARMACEUTICALS, INC. Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 30 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO, in the United States for the treatment of patients with HoFH. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com. ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT This press release includes forward-looking statements regarding Isis' alliance with Biogen Idec and the discovery, development, activity, therapeutic potential, safety and commercialization of ISIS-DMPKRx for the treatment of DM1. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company. Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc. KYNAMRO is a trademark of Genzyme Corporation. SOURCE Isis Pharmaceuticals, Inc. D. Wade Walke, Ph.D., Vice President, Corporate Communications and Investor Relations, 760-603-2741; or Amy Blackley, Ph.D., Associate Director, Corporate Communications, 760-603-2772 |
Posted at 22/7/2013 13:28 by bones CARLSBAD, Calif., July 22, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (ISIS) announced data from a Phase 2 study of ISIS-APOCIIIRx in patients with high to severely high triglycerides on stable doses of fibrates. In this study, patients treated with ISIS-APOCIIIRx experienced reductions of up to 70 percent in apolipoprotein C-III (apoC-III) and up to 64 percent in triglycerides. In addition, patients treated with ISIS-APOCIIIRx experienced an up to 52 percent increase in high-density lipoprotein cholesterol (HDL-C), the 'good' cholesterol, and an up to 77 percent reduction in apoC-III-associated very low-density lipoprotein (VLDL) particles. Isis is also evaluating ISIS-APOCIIIRx in this Phase 2 study as a monotherapy in patients with severely high triglycerides and plans to report these data at the European Society of Cardiology on August 31 in Amsterdam.The Phase 2 study of ISIS-APOCIIIRx was a double-blind, randomized, placebo-controlled 13-week study designed to assess the safety and activity of ISIS-APOCIIIRx. The portion of the study reported today was conducted in patients with high to severely elevated triglyceride levels (between 225 and 2,000 mg/dL) on stable doses of fibrates. Table 1: ISIS-APOCIIIRx Produced Statistically Significant Reductions of Triglycerides, ApoC-III and ApoC-III Associated VLDL in a Phase 2 Study in Patients With High Triglyceride Levels Treated With Stable Doses of Fibrates. Mean % Changes From Baseline at Primary Endpoint. (see link for the table as it doesn't format here) After 13 weeks of dosing, robust and prolonged, statistically significant mean percent reductions from baseline in apoC-III, triglycerides and VLDL-associated apoC-III particles were observed in both dose cohorts. Furthermore, patients treated with ISIS-APOCIIIRx demonstrated a rapid, prolonged and statistically significant mean percent increase from baseline in HDL-C in both dose cohorts with no statistically significant increase in low-density lipoprotein cholesterol (LDL-C) or non-HDL-C. The effects of ISIS-APOCIIIRx observed on these lipid parameters were in addition to those achieved with each patient's existing therapeutic regimen of fibrates. "Patients with very high levels of triglycerides are at significant risk for cardiovascular disease, diabetes, pancreatitis and other complications. For these patients, there are very limited treatment options. Fibrates have been shown to reduce triglycerides; however fibrate therapy is not always effective nor widely used by these patients," said Daniel Gaudet, M.D., Ph.D., from the department of medicine, University of Montreal and scientific director, Genome Quebec Biobank Technology Center. "The data presented today on ISIS-APOCIIIRx are very encouraging because they show that ISIS-APOCIIIRx is additive to fibrates and are consistent with Isis' previous Phase 2 data in patients with moderately elevated triglycerides and type 2 diabetes. In both studies, rapid, robust reductions in apoC-III and triglycerides were observed. The positive effect of ISIS-APOCIIIRx on other key lipid parameters demonstrates the potential for ISIS-APOCIIIRx to provide therapeutic benefit to patients with very high triglycerides." In this study, 26 patients received either 200 mg or 300 mg dose of ISIS-APOCIIIRx, or placebo via weekly subcutaneous injections. All patients were on stable doses of fibrates with average baseline levels of fasting triglycerides between 282 mg/dL and 457 mg/dL. The three groups of patients were reasonably well balanced in baseline characteristic. In this study ISIS-APOCIIIRx was found to be generally safe and well tolerated. The most common adverse event (AE) was injection site reactions, which were infrequent and consisted of mild erythema that typically resolved within one to two days. There were no flu-like symptoms, no elevations of liver enzymes greater than three times upper limit of normal, no abnormalities in renal function and no clinically meaningful changes in other laboratory values. There was one patient who, four days after treatment, experienced a transient episode of a rash, low-grade fever, chills and headache, which resolved completely. This event was reported by the investigator as related to treatment, and classified as a serum sickness-like reaction (a serious AE). Subsequent detailed investigations demonstrated that it was not serum sickness. "We are very encouraged by the two sets of positive data we have reported this summer demonstrating that treatment with ISIS-APOCIIIRx produced highly statistically significant and clinically meaningful reductions in apoC-III and triglycerides, and increases in HDL-C in patients with high triglycerides. In addition, the positive effect of ISIS-APOCIIIRx treatment on lipid parameters, improvements in glucose control and trends toward improvements in insulin sensitivity, suggest that ISIS-APOCIIIRx could have a broad therapeutic profile in addition to triglyceride lowering for patients with severely high triglycerides. We are also pleased with the data reported today. They demonstrate that ISIS-APOCIIIRx is additive to fibrates with robust reductions of apoC-III and triglycerides," said Richard Geary, Ph.D., senior vice president of development at Isis. "We look forward to sharing the results from our ongoing Phase 2 study evaluating ISIS-APOCIIIRx as a monotherapy in patients with severely high triglycerides. In this study, we hope to show that treatment with ISIS-APOCIIIRx in patients with severely high triglycerides also produces significant effects on apoC-III, triglycerides and HDL-C. Following completion of the Phase 2 program, we plan to discuss our Phase 3 plans with regulators and move rapidly into a Phase 3 program next year in patients with severely high triglycerides (greater than 880 mg/dL)." ISIS-APOCIIIRx is an antisense drug intended to treat patients with severely high triglycerides either as a single agent or in combination with other triglyceride-lowerin Conference Call At 8:30 a.m. Eastern Time today, July 22, 2013, Isis will conduct a live webcast and slide presentation conference call to discuss the positive Phase 2 data. Interested parties may listen to the call by dialing 866-652-5200, or access the webcast with or without audio at www.isispharm.com. A webcast replay will be available for a limited time at the same address. ABOUT ISIS PHARMACEUTICALS, INC. Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO, in the United States for the treatment of patients with HoFH. Genzyme is also pursuing marketing approval of KYNAMRO in other markets. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com. ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT This press release includes forward-looking statements regarding the discovery, development, and potential of drugs for cardiovascular diseases, and the development, activity, therapeutic potential and safety of ISIS-APOCIIIRx. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company. Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc. KYNAMRO is a trademark of Genzyme Corporation. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
